CSBR - CIK 0000771856
CHAMPIONS ONCOLOGY, INC. trades as CSBR. In its fiscal 2025 annual report the company posted revenue of $56.94M, up 13.5% from the prior year and net income of $4.70M. This page tracks CHAMPIONS ONCOLOGY, INC. through 647 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years CHAMPIONS ONCOLOGY, INC.'s revenue grew from $20.24M to $56.94M, a compound annual growth rate of 15.9%. Net profit margin expanded from -7.3% to 8.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-03-30 |
| Quarterly report | 10-Q | 2026-03-12 |
| Major company event | 8-K | 2026-03-12 |
| Insider trade | 4 | 2026-01-30 |
| Insider trade | 4 | 2026-01-30 |
| New insider ownership | 3 | 2026-01-16 |
| Quarterly report | 10-Q | 2025-12-15 |
| Major company event | 8-K | 2025-12-15 |
The largest companies sharing CHAMPIONS ONCOLOGY, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
CHAMPIONS ONCOLOGY, INC. reported revenue of $56.94M for fiscal year 2025, an increase of 13.5% year over year.
Yes. CHAMPIONS ONCOLOGY, INC. reported net income of $4.70M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.